anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To obtain a composition for preparing an external carbon dioxide preparation that is easily prepared in a short time, does not stain clothes etc., and provides stronger beauty and medical treatment effect in a short period.  <P>SOLUTION: The composition for preparing an external carbon dioxide preparation comprises a granule which comprises a water-soluble acid, a thickener and a water-soluble dispersant as essential components, wherein the thickener is mixed with the water-soluble acid and the water-soluble dispersant and a viscous composition that comprises a carbonate, water, a specific thickener and a polyhydric alcohol as essential components and is mixed with the granule in use. The water-soluble acid, the thickener and the water-soluble dispersant in the granule are mixed in a specific mixing ratio and the carbonate, water and the thickener in the viscous composition are mixed in a specific mixing ratio. The granule and the viscous composition are used in a specific ratio. Further, the thickener and the water-soluble dispersant of the granule are used in a specific combination.  <P>COPYRIGHT: (C)2009,JPO&INPIT
The invention discloses a health-care medicine formula with functions of enhancing immunity, alleviating physical fatigue and resisting tumor, and relates to a health care medicine. The health-care medicine formula comprises the following components in parts by weight: 6-15g of broccoli extractive, 9-20g of Astragalus mongholicus, 9-20g of salviae miltiorrhizae, 6-12g of dangshen, 6-12g of resveratrol, 0.04-0.1g of curcumin, 0.004-0.01g of selenium carrageenan and 2-10g of microcrystalline cellulose. The health-care medicine formula has the following preparation technology: firstly, respectively smashing the Astragalus mongholicus, the salviae miltiorrhizae, the dangshen and the resveratrol medicines, and sieving by a sieve with 60-80 meshes; respectively taking the powder, mixing the powder with other raw materials and auxiliary materials for 45-50 minutes; filling in a capsule; in the filling process, controlling the filling weight strictly according to the internally controlled standard; then screening, polishing, internally packing, and externally packing; and finally, checking according to the inspection standard, and putting into storage. The health-care medicine can help people to enhance the immunity, alleviating the physical fatigue, resisting the tumor, improving the immunity of the human body and improving the life quality of the patients. The health-care medicine formula does not have side effects or adverse reaction. Due to the adoption of the modern preparation technology and the advanced quality control method, the product is safe and stable and has controllable quality.
A fat suited as fat phase for the manufacture of low fat spreads which are stable at elevated ambient temperatures which fat comprises a mixture of triglycerides, in which—2.5 to 5.5 wt. % of the triglycerides are HHH triglycerides,—25 to 65 wt. %, preferably 25 to 55 wt. % of the HHH triglycerides are monoacid triglycerides and the remaining HHH triglycerides are composed of mixed fatty acid residues,—1.5 to 5 wt. % of the triglycerides are HHM and HMH triglycerides,—at least 85 wt. % of the fatty acid residues H in HHM and HMH are palmitic acid residues, where H denotes saturated fatty acid residues having chain lengths larger than 15 carbon atoms and M denotes saturated fatty acid residues having chain lengths of either 12 or 14 carbon atoms and where the M-residue is placed either in the middle or in one of the terminal positions. Such fat phase can be obtained by incorporating in a triglyceride oil a fat A and a fat B where the fat A and the fat B together amount to 6-15 wt. % of the fat and the A/B weigh ratio is in the range 1/9 to 4/6, characterized in that of fat A—at least 50 wt. % of the triglycerides are fully saturated—at least 80 wt. % of the constituting saturated fatty acid residues have a chain length of 16 carbon atoms (P) or 18 carbon atoms (S), the ratio P:S being in the range 75:25-25:75,—up to 5 wt. % of the saturated fatty acid residues have a chain length of 12 or 14 carbon atoms and in that of fat B—at least 20 wt. %, preferably at least 25 wt. % of the triglycerides consist of HHM and HMH triglycerides.
BACKGROUND: The association between the occlusion rate of the side branch arteries branching from the abdominal aortic aneurysm sac and aneurysm sac shrinkage is unclear. We aimed to evaluate the efficacy of preemptive embolization of multiple side branch arteries branching from the abdominal aortic aneurysm sac in early aneurysm sac shrinkage after endovascular aneurysm repair.
METHODS: Patients undergoing endovascular aneurysm repair of abdominal aortic aneurysms, with or without preemptive embolization of multiple side branch arteries, including the inferior mesenteric artery and lumbar arteries, between January 2016 and August 2021, were retrospectively evaluated. Preemptive embolization was introduced at our institution in January 2018 and has been performed in all patients who undergo endovascular aneurysm repair since then. We compared occlusion rates of the side branch arteries, frequency of type 2 endoleaks, changes in aneurysm sac size, percentage of aneurysm sac size decrease, and frequency of reduction in the aneurysm sac diameter by > 5 mm.
RESULTS: The study included 43 patients in the embolization group and 20 in the nonembolization group. Preemptive embolization was successfully performed without any ischemic complications. The total occlusion rate of side branch arteries was significantly higher in the embolization group than in the nonembolization group (70.2% vs. 29.3%, P < 0.05). At 24 months of follow-up, the type 2 endoleak frequency was significantly lower in the embolization group than in the nonembolization group (6.9% vs. 31.6%, P < 0.05). The frequency of reduction in the aneurysm sac diameter by > 5 mm was significantly higher in the embolization group than in the nonembolization group at 24 months (62.1% vs. 31.6% P < 0.05). The optimal cutoff value for the total occlusion rate of the side branch arteries to achieve reduction in the aneurysm sac diameter by > 5 mm at 24 months, after endovascular aneurysm repair, was 66.7% in all patients (area under the curve = 0.634; sensitivity = 62.5%; specificity = 70.8%). These findings suggest that occluding 66.7% or more of the side branch arteries may result in early aneurysmal shrinkage.
CONCLUSIONS: Preemptive embolization of multiple side branch arteries, branching from the abdominal aortic aneurysm sac, may contribute to early aneurysm sac shrinkage; this may serve as a marker for fewer late complications after endovascular aneurysm repair.
PROBLEM TO BE SOLVED: To obtain an oil-in-water type emulsion having excellent action on skin, excellent in persistency and useful for cosmetics, pharmaceuticals, sanitary uses by combining a specific silicone surfactant with a specific oil. SOLUTION: This emulsion is obtained by using a silicone surfactant having at least one anionic group with a first oil selected from volatile oil (e.g. isododecane), a poly(1-20)alkylsiloxane and their mixture. A silicone surfactant selected from a phosphoric acid salt, a sulfuric acid salt and a sulfonic acid salt and/or a carboxylic acid salt group is used as the surfactant. The silicone surfactant having the phosphoric acid salt includes preferably a compound of formula I  R1 is a group of formula II [Me is methyl; (a) and (b) are each 0-200; (c) is 1-200; R4 is phenyl, etc.; R5 is a group of formula III (x, y and z are each 0-20)]; (d) and (e) are each 1 or 2; M is H, Na, etc.}. The emulsion comprises 5-40wt.% fat phase (first oil), 0.5-15wt.% surfactant and 15-94.5wt.% water phase.
Doses of extended-release tablets are usually given b.i.d. (approximately 12-hour intervals). When initiating therapy with extended-release lithium, dosage must be individualized according to serum levels and clinical response.

When switching a patient from immediate-release capsules to the lithium carbonate extended-release tablets, give the same total daily dose when possible. Most patients on maintenance therapy are stabilized on 900 mg daily, e.g., 450 mg lithium carbonate extended-release b.i.d. When the previous dosage of immediate-release lithium is not a multiple of 450 mg, for example, 1500 mg, initiate lithium extended-release tablet at the multiple of 450 mg nearest to, but below, the original daily dosage, i.e., 1350 mg. When the two doses are unequal, give the larger dose in the evening. In the above example, with a total daily dosage of 1350 mg, generally 450 mg lithium carbonate extended-release should be given in the morning and 900 mg lithium carbonate extended-release in the evening. If desired, the total daily dosage of 1350 mg can be given in three equal 450 mg lithium carbonate extended-release doses. These patients should be monitored at 1 to 2 week intervals, and dosage adjusted if necessary, until stable and satisfactory serum levels and clinical state are achieved.

When patients require closer titration than that available with doses of lithium carbonate extended-release in increments of 450 mg, immediate-release capsules should be used.

Acute Mania \- Optimal patient response to lithium carbonate can usually be established and maintained with 1800 mg per day in divided doses. Such doses will normally produce the desired serum lithium level ranging between 1 and 1.5 mEq/L.

Dosage must be individualized according to serum levels and clinical response. Regular monitoring of the patient's clinical state and serum lithium levels is necessary. Serum levels should be determined twice per week during the acute phase, and until the serum level and clinical condition of the patient have been stabilized.

Long-Term Control - The desirable serum lithium levels are 0.6 to 1.2 mEq/L. Dosage will vary from one individual to another, but usually 900 mg to 1200 mg per day in divided doses will maintain this level. Serum lithium levels in uncomplicated cases receiving maintenance therapy during remission should be monitored at least every two months.

Patients unusually sensitive to lithium may exhibit toxic signs at serum levels below 1 mEq/L.

N.B. \- Blood samples for serum lithium determinations should be drawn immediately prior to the next dose when lithium concentrations are relatively stable (i.e., 8 to 12 hours after the previous dose). Total reliance must not be placed on serum levels alone. Accurate patient evaluation requires both clinical and laboratory analysis.

Elderly patients often respond to reduced dosage, and may exhibit signs of toxicity at serum levels ordinarily tolerated by younger patients.
Ono Pharma UK Ltd is the European subsidiary of Ono Pharmaceutical Co. Ltd. As the European Legal Representative of Ono Pharmaceutical Co. Ltd, Ono Pharma UK Ltd is carrying out this study.

This is a clinical study of ONO-4053 in healthy volunteers. This study consists of three parts. Part A will investigate the safety, tolerability and pharmacokinetics when single ascending doses of ONO-4053 are administered in a double-blind manner. Part B will investigate the pharmacokinetics of ONO-4053 in the fed and fasted state in an open-label manner. Part C will investigate the safety, tolerability and pharmacokinetics when multiple ascending doses of ONO-4053 are administered in a double-blind manner. Doses for Part B and C will be determined after data from Part A are available.
According to randomization policy, patients' will be allocated to two groups each one will include 30 subjects: Group I (the study group) in which the investigator will use a polypropylene wide pore soft mesh (Bard, USA). Group II (the control group) in which the investigator will use the same polypropylene mesh in association with Vicryl mesh (Polyglactin 910, VM95, Ethicon, Belgium). The mesh will be prepared by suturing the Vicryl and polypropylene mesh together after folding the edges (2 cm each) and its fixation with four full thickness corners Vicryl 2/0 stay sutures. Another four sutures anchoring the overlapped edges together will be applied at the center of each edge, after that, the mesh will be inserted intraperitoneally in an oblong fashion in defects above the point midway between the umbilicus and symphysis pubis and in horizontal fashion in defects in the hypogastric region with the Vicryl part facing the bowel. U sutures using polypropylene 0 will be applied through the whole thickness of the anterior abdominal wall in order to anchor the four angles of the mesh. Then, the turned over edges of the mesh will be fixed to the inner aspect of the abdominal wall using interrupted full thickness U sutures or mesh stapler (fascia stapler, Medtronic (covidien), USA) according to availability. The same technique will be used in the study group excluding the vicryl mesh. Following mesh fixation, a tailored viable part of the sac will be closed over the mesh to separate it from the subcutaneous tissue in order to minimize seroma formation. Follow-up data will be recorded in a proforma for each patient, noting intraoperative and postoperative complications and postoperative hospital-stay. Each patient will be examined by the surgical team in the Outpatient Clinic at postoperative days 7, 15, and 30 to assess early complications, and at 3 months for one year and every 6 months for 2 years, to assess late complications when necessary after making the scheduled telephone communication.
Acute gastroenteritis in pediatric patients represents a major cause of morbidity and mortality in children. Interleukins 6 (IL-6) and 8 (IL-8) have been intensely studied in relation to various inflammatory conditions, including acute gastroenteritis, as they are activated in response to infection. This review aims to evaluate the ability of IL-6 and IL-8 to distinguish between bacterial and viral etiologies of acute gastroenteritis in children and to assess whether their levels correlate with the severity of this condition in light of currently available data. A scientific database search was performed to identify studies that investigated the role of IL-6 and IL-8 in acute gastroenteritis in the pediatric population. We identified nine studies that matched the review's objective. Both cytokines show increased values in acute gastroenteritis, but IL-6 levels are significantly higher in cases of bacterial infections. IL-8 levels do not present an increase to the same extent in cases of bacterial diarrhea in children but seem to be associated with the severity of the disease. The lack of sufficient research focusing on IL-6 and -8 as diagnostic, prognostic and severity biomarkers of acute gastroenteritis in children leaves room for further research on this topic, which must include larger cohort studies.
Cancer cells employ glycolysis for their survival and growth (the "Warburg effect"). Consequently, surrounding cells including immune cells in the tumor microenvironment (TME) are exposed to hypoglycemic, hypoxic, and low pH circumstances. Since effector T cells depend on the glycolysis for their survival and functions, the metabolically harsh TME established by cancer cells is unfavorable, resulting in the impairment of effective antitumor immune responses. By contrast, immunosuppressive cells such as regulatory T (Treg) cells can infiltrate, proliferate, survive, and exert immunosuppressive functions in the metabolically harsh TME, indicating the different metabolic dependance between effector T cells and Treg cells. Indeed, some metabolites that are harmful for effector T cells can be utilized by Treg cells; lactic acid, a harmful metabolite for effector T cells, is available for Treg cell proliferation and functions. Deficiency of amino acids such as tryptophan and glutamine in the TME impairs effector T cell activation but increases Treg cell populations. Furthermore, hypoxia upregulates fatty acid oxidation via hypoxia-inducible factor 1α (HIF-1α) and promotes Treg cell migration. Adenosine is induced by the ectonucleotidases CD39 and CD73, which are strongly induced by HIF-1α, and reportedly accelerates Treg cell development by upregulating Foxp3 expression in T cells via A2AR-mediated signals. Therefore, this review focuses on the current views of the unique metabolism of Treg cells dictated by cancer cells. In addition, potential cancer combination therapies with immunotherapy and metabolic molecularly targeted reagents that modulate Treg cells in the TME are discussed to develop "immune metabolism-based precision medicine".
FIELD: medicine, particularly, medico-biological studies. SUBSTANCE: preparations for integral correction of metabolic acidosis and alkalosis are not described in literature. Object of invention is use of preparation "Namacyte" (carbostimulin) for integral correction of metabolic acidosis and alkalosis. This object is accomplished owing to capability of above said preparation to normalize acidic-alkaline status and metabolic processes occurring in tissues. EFFECT: normalization of acidic-alkaline status and metabolic processes. 4 tbl
Embodiments of the present disclosure provides a health passport for creating a next best decision for user safety in a real-time state. The system receives inputs from a user and service providers, and compliance and policy information and other data from data sources. The inputs, compliance and policy information and other data are automatically analysed in real-time to create a next best action decision matrix comprising next best action information to be suggested to the user. The next best information may include actions, alerts, warnings, and escalation models associated with the service providers. The movement, health data, and one or more dynamic factors of the user are monitored and accordingly status of the user is updated. The next best action information may be sent to the user based on the information in the database and monitoring of the user.
Hyperbaric Oxygen Therapy at 1.5 ATA (atmospheres absolute). The subjects will receive 40 low pressure HBOT's on a once/day, 5d/week eight week schedule.
PROBLEM TO BE SOLVED: To effectively utilize the strongly alkaline liquid which is prepd. by adopting a natural method not elucidatable by the conventional science in neutralizing the acid rail which brings about environment destruction and incurs damage on man and animals and is improving soil. SOLUTION: Seven kinds of ashes made from burned 'bamboo, straws, cedars, pines, cypresses, cherry trees and chestnut trees' are formed by obtaining the special processes without using chemicals at all and the raw materials compounded basically from these ashes are prepd. These raw materials are put into a vessel equipped with a filter device and the strongly alkaline liquid is collected without destroying the components containing therein. The raw materials formed by compounding the ashes of tress, chaff, weeds buckwheat husks, etc., are put as the additive raw materials into the vessel and the hot water set at the temp. necessary for extraction is poured therein. The strongly alkaline aq. soln. collected by filtration is collected without destroying the components contained therein. The strongly alkaline aq. solns. for different purposes are refined and effectively utilized.  The working stages for collecting the pulp of plants as well as the purification and sterilization necessary for effective utilization of marine product waste are simplified by utilizing such aq. solns.
BACKGROUND: Inappropriate prescribing (IP) is common in hospitalised older adults with frailty. However, it is not known whether the presence of frailty confers an increased risk of mortality and readmissions from IP nor whether rectifying IP reduces this risk. This review was conducted to determine whether IP increases the risk of adverse outcomes in hospitalised middle-aged and older adults with frailty.
METHODS: A systematic review was conducted on IP in hospitalised middle-aged (45-64 years) and older adults (≥ 65 years) with frailty. This review considered multiple types of IP including potentially inappropriate medicines, prescribing omissions and drug interactions. Both observational and interventional studies were included. The outcomes were mortality and hospital readmissions. The databases searched included MEDLINE, CINAHL, EMBASE, World of Science, SCOPUS and the Cochrane Library. The search was updated to 12 July 2024. Meta-analysis was performed to pool risk estimates using the random effects model.
RESULTS: A total of 569 studies were identified and seven met the inclusion criteria, all focused on the older population. One of the five observational studies found an association between IP and emergency department visits and readmissions at specific time points. Three of the observational studies were amenable to meta-analysis which showed no significant association between IP and hospital readmissions (OR 1.08, 95% CI 0.90-1.31). Meta-analysis of the subgroup assessing Beers criteria medicines demonstrated that there was a 27% increase in the risk of hospital readmissions (OR 1.27, 95% CI 1.03-1.57) with this type of IP. In meta-analysis of the two interventional studies, there was a 37% reduced risk of mortality (OR 0.63, 95% CI 0.40-1.00) with interventions that reduced IP compared to usual care but no difference in hospital readmissions (OR 0.83, 95% CI 0.19-3.67).
CONCLUSIONS: Interventions to reduce IP were associated with reduced risk of mortality, but not readmissions, compared to usual care in older adults with frailty. The use of Beers criteria medicines was associated with hospital readmissions in this group. However, there was limited evidence of an association between IP more broadly and mortality or hospital readmissions. Further high-quality studies are needed to confirm these findings.
The present invention discloses a delicious hot crisp chili and a production method thereof. The present invention has a formula which comprises dry chili segments, sesame, peanuts, vegetable oil, lard oil, table salt, rice flour, dried orange peel, aniseed, rose pelargonium herb, white atractylodes rhizome, rhizoma, fructus tsaoko, pepper, spice with thirteen tastes and gourmet powder. The production method comprises the procedures: dry chilies are cut and washed for standby, auxiliary material is filled, and the mixture is fried, dewatered and cooked until the mixture is medium well; the mixture and auxiliary material juice for standby are simultaneously put in a pot to be fried until the mixture is ripened, rest heat is then preserved by weak fire, ripe peanut kernels are put and uniformly mixed, the mixture is taken out of the pot, and a finished product is obtained. The product is obtained by cooling and subsequently packaging the finished product. The product which is made by the method can be packaged into food which is immediately eaten after being opened, can be used for cooking dishes, and can also be used as seasoning for dressing cold dishes. The delicious hot crisp chili has spicy, hot, fresh and fragrant taste, and is used for being eaten together with rice, noodles, rice flour or wine, etc. The present invention is an ideal health-care green food.
Period 1: Oral dose of 15 mg unlabeled ertugliflozin + intravenous (IV) dose of 100 µg 14\^C-labeled ertugliflozin containing approximately 400 nCi 14\^C. The 14\^C IV dose will be administered as an infusion over approximately 5 minutes starting at 55 minutes after the unlabeled oral dose. → Period 2: Oral dose 15 mg unlabeled ertugliflozin + oral dose of 100 µg 14\^C-labeled ertugliflozin containing approximately 400 nCi 14\^C. Both the unlabeled and 14\^C-ertugliflozin will be administered at the same time (no more than 5 minutes apart). Dosing in Periods 1 and 2 will be separated by a washout of at least 11 days.